New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
07:26 EDTOMPI, VRXValeant price target raised to $80 from $70 at RBC Capital
RBC Capital increased its price target on Valeant (VRX) to reflect the Obagi (OMPI) acquisition, higher conviction levels for IDP-108 launch and an expected increase to 2013 guidance during the Q1 results conference call. The firm doesn't see the Obagi deal as transformational for Valeant but does expect it to generate at least $40M in synergies. RBC maintains an Outperform rating on Valeant.
News For VRX;OMPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
10:53 EDTVRXAckman says 'will take hard look' at Valeant shares after restrictions end
Subscribe for More Information
December 9, 2014
09:31 EDTVRXZoetis drops after report of Valeant abandoning growth by acquisitions strategy
Subscribe for More Information
06:39 EDTVRXValeant to abandon growth by acquisitions strategy, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use